Syfovre (pegcetacoplan)
- Region
- 🇪🇺 EU
- Active substance
- pegcetacoplan
- Company
- Apellis Europe B.V.
- Status
- Refused
- Therapeutic area
- Macular Degeneration; Geographic Atrophy
- CHMP opinion
- Thu 19 Sep 2024
- Application
- EMEA/H/C/005954
- ATC
- S01XA31
- Official record
- www.ema.europa.eu
Indication
Treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Aspaveli Authorised · Swedish Orphan Biovitrum AB (publ)
Follow Syfovre
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.